NeoGenomics, Inc. (NASDAQ:NEO) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET
Company Participants
Kendra Sweeney - VP of IR
Chris Smith - CEO
Jeff Sherman - CFO
Warren Stone - Chief Commercial Officer
Nate Montgomery - Director of Molecular Pathology
Melody Harris - Chief Operations Officer and President, Informatics
Karim Saad - Medical Laboratory Technologist
Alicia Olivo - EVP, General Counsel and Business Development
Conference Call Participants
Andrew Brackman - William Blair
Dan Brennan - TD Cowen
David Westenberg - Piper Sandler
Matt Sykes - Goldman Sachs
John Kim - Bank of America
Mark Massaro - BTIG
Matt Hewitt - Craig-Hallum Capital Group
Mike Matson - Needham and Company
Puneet Souda - Leerink Partners
Thomas DeBourcy - Nephron Research LLC
Operator
Welcome to the NeoGenomics Second Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Please note this call is being recorded and an audio replay will be available on the Company's website.
Kendra Sweeney, Vice President of Investor Relations, you may begin your conference.
Kendra Sweeney
Thank you, John. Good afternoon, everyone, and welcome to the NeoGenomics second quarter 2024 financial results call. With me today to discuss the results are Chris Smith, Chief Executive Officer; and Jeff Sherman, Chief Financial Officer. Additional members of the management team are available for Q&A, including Warren Stone, Chief Commercial Officer; Melody Harris, Chief Operations Officer and President of Informatics; Dr. Nate Montgomery, Head of Medical, and Karim Saad, Head of Strategy and Transformation. This call is being simultaneously webcast. We'll be referring to a slide presentation that has been posted to the investors tab on our website at ir.neogenomics.com.
Starting on Slide two, during this call, we will make forward-looking statements regarding our anticipated future performance. We caution you that such statements reflect our best judgment based on factors currently known to us and that actual events or results could differ materially. Please refer to our most recent forms 10-K, 10-Q, and 8-K we filed with the SEC to identify important risks and other factors that may cause our actual results to differ materially from the forward-looking statements.
The forward-looking statements made during this call speak only as of the original date of the call, and we undertake no obligation to update or revise any of these statements. During this call, we refer to certain non-GAAP financial measures that involve adjustments to GAAP results. The non-GAAP financial measures presented should not be considered in an alternative to the financial measures required by GAAP and are unlikely to be comparable to non-GAAP financial measures provided by other companies.